Summary 5.6-Dimethylxanthenone4-acetic acid (5.6-MeXAA) is a fused tricyclic analogue of flavone acetic acid (FAA) which was developed in an attempt to improve on the activity of FAA. Previous studies have shown 5.6-MeXAA to be curative in 80% of mice bearing colon 38 tumours and 12 times more dose potent than FAA. This investigation has demonstrated that a murine colon tumour cell line (MAC1SA) is approximately 60 times more sensitive to 5.6-MeXAA than to FAA. although these differences were not seen in three human cell lines tested. 5,6-MeXAA caused significant blood flow shutdown and haemorrhagic necrosis in subcutaneous MAC15A tumours in syngeneic and nude hosts. but measurable changes in tumour volume were seen only in syngeneic hosts. 5,6-MeXAA was inactive against intraperitoneal MACISA but produced significant anti-tumour effects against the same cell line inoculated via an intravenous route. FAA has been shown previously to be inactive in this model. Interestingly, the effects against lung colonies were not accompanied by obvious necrotic changes, suggesting that they may be the result of increased direct cytotoxicity rather than an indirect host mechanism. Further studies to investigate the effects against systemic tumour deposits are under way.
Flavone acetic acid (FAA) is a synthetic flavonoid which was selected for clinical trials on the basis of its anti-tumour activity against a wide range of murine subcutaneously (s.c.) transplantable solid tumours which are generally refractive to conventional cytotoxic agents (Corbett et al., 1986; Plowman et al., 1986; Bibby et al., 1987) . Clinical trials, however, showed that the promising activity observed in these murine models was not repeated in cancer patients, as the compound was found to be inactive against all tumour types tested (Kerr et al., 1989) .
In vitro data suggest that FAA possesses very little direct cytotoxic activity, requiring long exposure times and high concentrations to kill any of the cell lines tested (Bibby et al., 1987; Capolongo et al., 1987; Schroyens et al., 1987) , and therefore an indirect mechanism of action was proposed. Studies by Bibby et al. (1989a) Bibby et al., 1989b; Hill et al., 1989; Zwi et al., 1989 ). An immunomodulatory effect was also implicated (Ching and Baguley, 1987; Hornung et al., 1988; Wiltrout et al., 1988) , and previous studies in this laboratory have shown that the immune status of the mouse is important, as no objective responses were observed in s.c. tumours transplanted in thymectomised and nude mice although haemorrhagic necrosis and a reduction in tumour blood flow did occur (Bibby et al., 1991) . Lack of activity in nude mice is not universal as studies in other laboratories have demonstrated modest responses in tumours in immune compromised mice (Pratesi et al., 1990; Ching et al., 1992) . The production of both tumour necrosis factor alpha (TNF-a) (Mahadevan et al., 1990) Even though FAA was clinically disappointing, investigation has continued, because of the unusual mechanism of action, into the development of a series of analogues. These are based largely around the structurally related xanthenone chromophore Rewcastle et al.. 1989 Rewcastle et al.. , 1991a . From these studies 5,6-dimethylxanthenone-4 acetic acid (5,6-MeXAA, Figure 1 ) was found to exhibit increased dose potency against s.c. murine tumours (Rewcastle et al., 1991a) and was selected for further evaluation including a pharmacokinetic study (McKeage et al., 1991) and demonstration of stimulation of nitric oxide production from activated macrophages (Thomsen et al., 1990 (Thomsen et al., , 1991 (Thomsen et al., , 1992 Veszelovszky et al., 1993 ). An earlier study also demonstrated that 56-MeXAA is more effective than FAA at producing measurable growth delays in colon 38 tumours growing in nude mice In vitro studies Ascitic MAC15A cells, obtained as described above, and HRT-18 (Tompkins et al., 1974) and HT-29 (Fogh and Trempe, 1975) cell lines derived from human prnmary adenocarcinomas of the large bowel, were routinely maintained as monolayer cultures in RPMI tissue culture medium supplemented with 10% fetal calf serum, sodium pyruvate (I mM), penicillin/streptomycin (50 IU ml', 50pgml-') and L-glutamine (2 mM) at 37C. K562 human chronic myelogenous leukaemia-derived cells (Lozzio and Lozzio, 1975) were maintained as a suspension culture in complete RPMI. Subconfluent cells were used for all assays, and all assays were performed in triplicate. Cytotoxicity was ass over a range of 5,6-MeXAA or FAA concentrations in a continuous 96h exposure assay. Cell survival was assessed using the MTT assay (Carmichael et al., 1987) respectively. The effect of i.p. administered 5,6-MeXAA on day 5 s.c. MACI 5A tumours was significantly different for NMRI and nude hosts. Growth delay was calculated as the difference in time taken for the median control and treated tumours to reach relative tumour volume 2. In nude mice 25mgkg-' 5,6-MeXAA had no statistically significant effect on tumour growth in two independent experiments ( Figure  2a) , however on increasing this dose to 30mgkg-' a small growth delay of 4.2 days was observed but deaths were seen. 5,6-MeXAA showed a highly significant effect against MAC15A tumours in NMRI mice, with tumour regression and a 13.3 day growth delay (P<0.01) observed at 28mg kg-' (Figure 2b) . A similar delay (16.3 days) was observed when the experiment was repeated independently.
Histological examination of treated s.c. tumours revealed large areas of haemorrhagic necrosis 24h after treatment (Figure 3a) 11%. These were similar to those observed in NMRI mice with 9.2%, 97% and 89% area necrosis observed in control tumours and tumours treated with 25 mg kg-' 5,6-MeXAA and 28 mg kg-' 5,6-MeXAA respectively. Tumour blood volume measurements as assessed by the Evans blue dye perfusion assay are presented in Tables III  and IV . Data showed that tumour blood volume was reduced on administration of 5.6-MeXAA (28 mg kg-1) in NMRI mice from mean control levels of 23 lg g-' tumour to 18 Lgg-at 2h and 8.5igg-' at 4h. Blood volumes remained reduced after 24 h (10 gg g-'). A similar pattern was observed in nude mice after 30 mg kg-' 5,6-MeXAA, 23 pg g-' control levels being reduced to 11 ig g-' at 2 h and 6.1g g-g' at 4 h. Deaths occurred within 24 h at 30 mg kg-' so the experiment was repeated at 25 mg kg-', and at this dose level Evans blue concentration within the tumour was reduced to a mean level of 6.3 fgg-'.
When MAC1SA tumour cells were grown i.p. in NMRI mice, no increase in the median survival time was observed for the group treated on day 2 (30mgkg-1, 5,6-MeXAA) compared with the control (MST: 8.0 days, treated; 7.5 days, control).
Activity was noted against MAC15A systemic tumours in NMRI mice when assessed by both the comparison of MST and the lung colony counting method (Tables V and VI) .
Following 5,6-MeXAA (30mg kg-') the MST increased significantly by 70% (P<0.01), although there was one acute death. This dose also reduced significantly the number of colonies counted in a separate expenment (P<0.05), but the effect was not as prominent at the reduced dose of 27.5 mg kg'.
Histological evaluation of H&E-stained sections showed that no necrosis was present within these tumours ( Figure  3b ). Necrosis was also not observed when the lung tumours were allowed to develop for 7 days before treatment with 5,6-MeXAA at single i.p. doses of either 25 mg kg-', 28 mg kg-l or 30 mg kg-'.
Discusio
This study set out to evaluate further the preclinical activity of 5,6-MeXAA with a view to providing additional information which might guide future clinical investigations; in particular, it was important to investigate the compound in situations in which FAA was ineffective. Previous studies have demonstrated increased potency compared with FAA (Rewcastle et al., 1991a) and increased activity against colon 38 tumours in nude mice Examination of the effects of 5,6-MeXAA against the sensitive MAC15A cell line transplanted s.c. into NMRI mice confirmed the earlier colon 38 data in that dramatic tumour growth delays were seen. However, unlike the colon 38, no anti-tumour effects were detected in nude hosts by tumour volume measurements. More detailed study of the effects of 5,6-MeXAA revealed a similar degree of vascular shutdown in both hosts. Objective measurements of necrosis failed to reveal any differences between treated tumours in either host, with similar massive haemorrhagic necrosis being seen in each case. In this respect 5,6-MeXAA appears similar to FAA (Bibby et al.. 1991) . It is likely that better tumour models of the actual clinical targets for chemotherapy might better predict clinical outcome, but although inoculation of a cell suspension into a mouse has clear limitations in this respect it does at least give the opportunity to assess some aspects of systemic disease. As outlined earlier, FAA was shown to be inactive against MAC 1 5A cells grown within the peritoneal cavity or systemically (Bibby et al., 1989a) , although there were dramatic anti-tumour effects when the same cell line was allowed to develop into established s.c. tumours. Since FAA has also been shown to be inactive in the clinic, it was thought that additional useful information on 5,6-MeXAA might be obtained by evaluating it against i.p. and i.v. inoculated cells, initially in syngeneic hosts, in addition to studies on s.c. tumours. This study showed the compound to be inactive against i.p. tumour cells, although activity was seen when the i.v. model was examined, suggesting that the increased potency of 5,6-MeXAA over FAA might be a useful property. Histological examination of lung deposits from either control mice or those treated with (and responding to) 5,6-MeXAA failed to reveal any signs of haemorrhagic necrosis. A further experiment allowed tmour nodules to develop for 7 days before treatment, but these also did not become necrotic. It is important to realis that even in these more established tumour nodules there is no neovasculature and the deposits are smaler than the s.c. tumours treated in these studies. Survival studies have not been carried out against these more advanced systemic tumours. The observations to date provide evidence that the mechanism of action against systemic (lung) deposits is different from, or at least lacks some of the features of, that occurring against s.c. 
